|
|
|
MIRA
INFORM REPORT
|
Report No. : |
508786 |
|
Report Date : |
15.05.2018 |
IDENTIFICATION DETAILS
|
Name : |
WEIHAI DISU PHARMACEUTICAL CO,. LTD. |
|
|
|
|
Registered Office : |
No. 268 Tianrun Road, Wendeng Economic Development Zone, Weihai City,
Shandong Province |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2017 |
|
|
|
|
Date of Incorporation : |
13.05.2005 |
|
|
|
|
Unified Social
Credit Code : |
91371000774197249X |
|
|
|
|
Legal Form : |
Limited Liabilities Company |
|
|
|
|
Line of Business : |
Subject is mainly engaged in manufacture and sales of chemical drug
raw materials. It has more than 50 kinds of products, including loxoprofen
sodium, candesartan cilexetil, flavoxate hydrochloride, levamlodipine
besylate, glipizide. |
|
|
|
|
No. of Employees : |
5,000 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Slow but Correct |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s, China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role. China has implemented reforms in a gradualist fashion, resulting in efficiency gains that have contributed to a more than tenfold increase in GDP since 1978. Reforms began with the phaseout of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China continues to pursue an industrial policy, state support of key sectors, and a restrictive investment regime. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2016 stood as the largest economy in the world, surpassing the US in 2014 for the first time in modern history. China became the world's largest exporter in 2010, and the largest trading nation in 2013. Still, China's per capita income is below the world average.
After keeping its currency tightly linked to the US dollar for years, China in July 2005 moved to an exchange rate system that references a basket of currencies. From mid-2005 to late 2008, the renminbi appreciated more than 20% against the US dollar, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing announced it would allow a resumption of gradual liberalization. From 2013 until early 2015, the renminbi (RMB) appreciated roughly 2% against the dollar, but the exchange rate fell 13% from mid-2015 until end-2016 amid strong capital outflows in part stemming from the August 2015 official devaluation; in 2017 the RMB resumed appreciating against the dollar – roughly 7% from end-of-2016 to end-of-2017. From 2013 to 2017, China had one of the fastest growing economies in the world, averaging slightly more than 7% real growth per year. In 2015, the People’s Bank of China announced it would continue to carefully push for full convertibility of the renminbi, after the currency was accepted as part of the IMF’s special drawing rights basket. However, since late 2015 the Chinese Government has strengthened capital controls and oversight of overseas investments to better manage the exchange rate and maintain financial stability.
The Chinese Government faces numerous economic challenges including: (a) reducing its high domestic savings rate and correspondingly low domestic household consumption; (b) managing its high corporate debt burden to maintain financial stability; (c) controlling off-balance sheet local government debt used to finance infrastructure stimulus; (d) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and college graduates, while maintaining competitiveness; (e) dampening speculative investment in the real estate sector without sharply slowing the economy; (f) reducing industrial overcapacity; and (g) raising productivity growth rates through the more efficient allocation of capital and state-support for innovation. Economic development has progressed further in coastal provinces than in the interior, and by 2016 more than 169.3 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of China’s population control policy known as the “one-child policy” - which was relaxed in 2016 to permit all families to have two children - is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and urbanization. The Chinese Government is seeking to add energy production capacity from sources other than coal and oil, focusing on natural gas, nuclear, and clean energy development. In 2016, China ratified the Paris Agreement, a multilateral agreement to combat climate change, and committed to peak its carbon dioxide emissions between 2025 and 2030.
The government's 13th Five-Year Plan, unveiled in March 2016, emphasizes the need to increase innovation and boost domestic consumption to make the economy less dependent on government investment, exports, and heavy industry. However, China has made more progress on subsidizing innovation than rebalancing the economy. Beijing has committed to giving the market a more decisive role in allocating resources, but the Chinese Government’s policies continue to favor state-owned enterprises and emphasize stability. Chinese leaders in 2010 pledged to double China’s GDP by 2020, and the 13th Five Year Plan includes annual economic growth targets of at least 6.5% through 2020 to achieve that goal. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. Chinese leaders also have undermined some market-oriented reforms by reaffirming the “dominant” role of the state in the economy, a stance that threatens to discourage private initiative and make the economy less efficient over time. The slight acceleration in economic growth in 2017—the first such uptick since 2010—gives Beijing more latitude to pursue its economic reforms, focusing on financial sector deleveraging and its Supply-Side Structural Reform agenda, first announced in late 2015.
|
Source
: CIA |
INVESTIGATION RECORD
|
Name of Interviewee |
Ms. Yin Xiangrong |
|
Tel |
(86 631) 3857771/3857101 |
|
Investigation Way |
Telephone |
ORDER DETAILS & INVESTIGATION RESULTS
|
- |
Order Information |
Verification |
|
Name(English) |
Weihai Disu Pharmaceutical Co., Ltd |
Correct |
|
Address (English) |
No 55, Way of Qilu Road, Weihai Economic & Techological
Development Zone Shandong, P.R. |
One of subject's factory addresses |
ABSTRACT
|
Name (English) |
WEIHAI DISU PHARMACEUTICAL CO,. LTD. (Given by Official Sources) |
|
Unified Social Credit Code |
91371000774197249X |
|
AIC registration No. |
370000400004172 |
|
National Organization Code |
774197249 |
|
Company Status |
Operational |
|
Executive |
Zhang Baojun |
|
Registered Capital |
CNY 90,000,000.00 |
|
Date of Establishment |
2005-05-13 |
|
Employee |
5,000 |
|
Company Size |
Large |
|
SIC (China) |
2710,Production of Original Medicine of Chemical Drugs |
|
Import and Export Enterprise Code |
3700774197249 |
|
Import/Export Permit |
Yes |
CONTACTS
|
Tel |
(86 631)3857771/3857101 |
|
Address |
No. 268 Tianrun Road, Wendeng Economic Development Zone, Weihai City,
Shandong Province(Office; Plant; Storage) |
|
Address Post code |
264200 |
|
Ownership |
Owned |
|
RISK ANALYSIS |
|
Established in May 2005 with the registered capital of CNY 90,000,000.00,
subject is mainly engaged in manufacture and sales of chemical drug raw
materials. With long history, the company has accumulated rich industry
experience. Currently, with large business scale, it enjoys high popularity
and influence in the industry. According to subject's current financial information, its operating
income of 2017 increases over that of 2016, indicating its business was
developed well in 2017. High profit indices of 2017 reflect the company’s
profitability is good. With low turnover of total assets and turnover of
current assets in 2017, SC has poor operation capability. As a whole, with
low liabilities to assets ratio of 2017, subject’s long-term solvency is
good. According to subject's current ratio and quick ratio in 2017, its short-term
solvency is poor. |
REGISTRATION INFORMATION
|
Unified Social Credit Code |
91371000774197249X |
|
AIC registration No. |
370000400004172 |
|
Date of Establishment |
2005-05-13 |
|
Registered Address |
No. 268 Tianrun Road, Wendeng Economic Development Zone, Weihai City,
Shandong Province |
|
Registry |
Market Supervision Administration – Wendeng Dist, Weihai City |
|
Legal Representative |
Zhang Baojun |
|
Legal Form |
Limited Liabilities Company |
|
Registered Capital |
CNY 90,000,000.00 |
|
Latest Year of Annual Report |
2016 |
|
Operation duration |
Perpertual |
|
Business Scope |
Development, production and sales of API; Development, production and sales of non-sterile API; Production, sales and research and development of new materials for
marine life; Import and export of goods and technology; Research and development and transfer, consulting services of medical
technology; Research, development and transfer of natural substances extraction,
separation and purification technology; Extraction and sales of natural products from plants and ores; Production and sales of fine chemical products; Export business of API and fine chemical products; Production and sales of clothing, textiles, general merchandise,
stationery, food and food additives; Sales of health products, cosmetics, hygiene products, kitchen
utensils, household appliances, cleaning products and health care equipment. |
REGISTRATION CHANGES
|
- |
Date |
Item Changed |
From |
To |
|
1 |
2017-07-17 |
Registered capital |
CNY10,000,000.00 |
CNY90,000,000.00 |
|
2 |
2016-12-07 |
Registered address |
East of Andong Road, South of Guangzhou East Road, Wendeng Economic
Development Zone, Weihai City, Shandong Province |
No. 268 Tianrun Road, Wendeng Economic Development Zone, Weihai City,
Shandong Province |
|
3 |
2016-11-04 |
Registered address |
West of Wuzhu River, East of 3# Road, North of 19# Road, South of 18#
Road, Gushan Town, Weihai Economic Development Zone |
East of Andong Road, South of Guangzhou East Road, Wendeng Economic
Development Zone, Weihai City, Shandong Province |
|
4 |
2013-02-01 |
Registered capital |
CNY1,360,000.00 |
CNY10,000,000.00 |
|
5 |
2011-05-04 |
Registered address |
No. -55-5 Qilu Avenue, Economic and Technological Development Zone,
Weihai City |
West of Wuzhu River, East of 3# Road, North of 19# Road, South of 18#
Road, Gushan Town, Weihai Economic Development Zone |
|
6 |
2011-02-18 |
Registered address |
No. -196 Keji Road, Weihai Torch High Technology Industrial
Development Zone |
No. -55-5 Qilu Avenue, Economic and Technological Development Zone,
Weihai City |
|
7 |
2007-07-09 |
Registered capital |
CNY1,000,000.00 |
CNY1,360,000.00 |
|
8 |
2006-04-20 |
Registered address |
No. -196 Keji Road, High Technology Industrial Development Zone,
Weihai City |
No. -196 Keji Road, Weihai Torch High Technology Industrial
Development Zone |
SHAREHOLDER INFORMATION
|
- |
Name |
% Ownership |
Capital Contributed |
Currency |
Investment Way |
Paid-in % |
Country |
|
1 |
DISHA PHARMACEUTICAL GROUP SHANDONG DISHA MEDICINE MARKETING COMPANY |
100.00 |
90,000,000.00 |
CNY |
- |
- |
China |
|
Total |
|
100.0 |
90,000,000 |
|
|
|
|
ENTITY SHAREHOLDER
|
Name (English) |
DISHA PHARMACEUTICAL GROUP SHANDONG DISHA MEDICINE MARKETING COMPANY |
|
Country |
China |
|
Legal Representative |
Liu Xinbo |
|
Registration No. |
370611228008609 |
|
Unified Social Credit Code |
91371081755404361M |
|
Date of Establishment |
2003-09-30 |
|
Legal Form |
Limited Liabilities Company |
|
Registered Capital |
CNY 97,353,008.00 |
|
Status |
Operational |
|
Registered Address |
No. 69 Guangzhou East Road, Wendeng Economic Development Zone, Weihai
City, Shandong Province |
ULTIMATE HOLDING
|
- |
Ultimate Shareholder |
Investment Way |
|
1 |
Wang Dejun |
- |
|
English Name |
Wang Dejun |
|
Country |
China |
|
Type |
Natural person shareholder |
|
Note |
Wang Dejun --67.83% Weihai Disha Investment Co., Ltd. --99.17% DISHA PHARMACEUTICAL GROUP CO.,LTD. --89.73% DISHA PHARMACEUTICAL GROUP SHANDONG DISHA MEDICINE MARKETING
COMPANY --100.00% WEIHAI DISU PHARMACEUTICAL CO,. LTD. |
No branch information of subject is searched out from database.
INVESTMENT IN OTHER COMPANIES
|
- |
Name |
License Status |
Share Holding |
Currency |
% Ownership |
|
1 |
Tianjin Disha Pharmaceutical Technology
Development Co., Ltd. |
Operational |
20,000,000.00 |
CNY |
100.00% |
|
Name (English) |
Tianjin Disha Pharmaceutical Technology Development Co., Ltd. |
|
Unified Social Credit Code |
91120116MA06BDKA7F |
|
License Status |
Operational |
|
Registration No. |
120116000697646 |
|
Name Of Legal Representative |
Bian Jianhua |
|
Legal Form |
Limited Liabilities Company |
|
Country |
China |
|
Registered Capital |
CNY 20,000,000.00 |
|
Type |
Subsidiary |
|
Date of Establishment |
2018-04-17 |
|
Share Holding |
20,000,000.00 |
|
Currency |
CNY |
|
% Ownership |
100.00% |
MANAGEMENT
|
Name |
Zhang Baojun |
|
Position |
Chairman |
INVOLVEMENT IN
OTHER COMPANIES
|
- |
Name (English) |
License Status |
Legal Representative |
Position |
Type of Engagement |
|
1 |
HEBI FEIHE SHARE CO.,LTD. |
Operational |
NO |
Director |
Investment(0.13%) |
|
2 |
Weihai Dijia Group Co., Ltd. |
Operational |
NO |
General Manager |
Directorship |
|
3 |
Weihai Aonisite Environmental Protection
Technology Co., Ltd. |
Operational |
YES |
Executive director |
Directorship |
|
Name (English) |
HEBI FEIHE SHARE CO.,LTD. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Jia Shenju |
|
Registered Capital |
CNY 127,346,510.00 |
|
Country |
China |
|
Registration No. |
410600100001932 |
|
Unified Social Credit Code |
914106001726317578 |
|
Legal Form |
Shares Limited Company (Unlisted) |
|
Share Holding |
169,680.00 |
|
Currency Of Share Holding |
CNY |
|
Way of Investment |
Capital |
|
% Ownership |
0.13 |
|
Position |
Director |
|
Date of Establishment |
1996-11-18 |
|
Name (English) |
Weihai Dijia Group Co., Ltd. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Wang Linjia |
|
Registered Capital |
CNY 100,000,000.00 |
|
Country |
China |
|
Registration No. |
371081200016346 |
|
Unified Social Credit Code |
91371081062986928J |
|
Legal Form |
Limited Liabilities Company |
|
Position |
General Manager |
|
Date of Establishment |
2013-03-07 |
|
Name (English) |
Weihai Aonisite Environmental Protection Technology Co., Ltd. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Zhang Baojun |
|
Registered Capital |
CNY 10,000,000.00 |
|
Country |
China |
|
Registration No. |
371081200035164 |
|
Unified Social Credit Code |
91371081334416647M |
|
Legal Form |
Limited Liabilities Company |
|
Position |
Executive director |
|
Date of Establishment |
2015-04-16 |
MANAGEMENT
|
- |
Name |
Position |
Gender |
|
1 |
Zhang Mingtao |
General Manager |
- |
|
2 |
Zhang Baojun |
Chairman |
- |
DIRECTORS AND SUPERVISORS
|
- |
Name |
Position |
Gender |
|
1 |
Zhang Baojun |
Chairman |
- |
|
2 |
Liu Bingpeng |
Director |
- |
|
3 |
Wang Dejun |
Director |
- |
|
4 |
JUDICIAL INFORMATION
As of the reporting date, no related record about subject is found
through below sources:
A. Website of China Court Organization;
B. Websites of local courts of subject's location;
C. Websites of major domestic courts;
D. Judicial information of database.
As of the reporting date, no related record about subject is found
through below sources:
A. Website of China Court Organization;
B. Websites of local courts of subject's location;
C. Websites of major domestic courts;
D. Judicial information of database.
CIVIL & COMMERCIAL TRIAL PROCESS
As of the reporting date, no related record about subject is found
through below sources:
A. Website of China Court Organization;
B. Websites of local courts of subject's location;
C. Websites of major domestic courts;
D. Judicial information of database.
CIVIL & COMMERCIAL JUDGMENT DOCUMENT
As of the reporting date, no related record about subject is found
through below sources:
A. Website of China Court Organization;
B. Websites of local courts of subject's location;
C. Websites of major domestic courts;
D. Judicial information of database.
ADMINISTRATIVE ILLEGAL RECORDS
As of the reporting date, no related record about subject is found
through below sources:
A. Website of China Court Organization;
B. Websites of local courts of subject's location;
C. Websites of major domestic courts;
D. Judicial information of database.
OPERATION INFORMATION
|
Main Business |
Manufacture and sales of chemical drug raw materials |
|
Products & Service |
SC is mainly engaged in manufacture and sales of chemical drug raw
materials. It has more than 50 kinds of products, including loxoprofen
sodium, candesartan cilexetil, flavoxate hydrochloride, levamlodipine
besylate, glipizide, etc. |
|
Production Information |
SC can process 2 billions tons of APIs and intermediates per year. |
OPERATION FACILITIES
|
Business Address |
No. 268 Tianrun Road, Wendeng Economic Development Zone, Weihai City,
Shandong Province(Office; Plant; Storage) |
|
Tel |
(86 631)3857771/3857101 |
|
Post code |
264200 |
|
Environment |
Major industrial areas |
|
Land Area |
180 Mu |
|
Ownership |
Owned |
|
Traffic Condition |
Convenient |
|
Business Address |
No. 55 Qilu Avenue, Economic and Technological Development Zone,
Weihai City, Shandong Province(Office; Plant; Storage) |
|
Post code |
264205 |
|
Environment |
Major industrial areas |
|
Ownership |
Unknown |
|
Traffic Condition |
Convenient |
|
Region |
Products |
Customer Type |
Number of Customers |
Payment Terms |
Region |
Percentage |
|
|
Domestic |
Chemical APIs |
Pharmaceutical manufacturers, traders, etc |
Over 20 |
Prompt payment, advance payment, payment by contract, etc. |
All over China |
80 |
|
|
International |
Chemical APIs |
Pharmaceutical manufacturers, traders, etc |
Over 10 |
L/C, T/T, etc. |
South Korea, Japan, India, Taiwan, Bangladesh, etc. |
20 |
|
|
OTHER INFORMATION |
SC's products are sold at home and abroad, mainly in domestic market.
The exporting areas are South Korea, Japan, India, Taiwan, Bangladesh, etc.
The products are sold directly or on commission. With years of operation,
subject has established stable sales channels. |
||||||
PURCHASE INFORMATION
|
Region |
Main Products Purchased |
Number of Suppliers |
Payment Terms |
Region |
Percentage |
|
|
Domestic |
Production equipment, environmental protection equipment, testing
device, chemical raw materials, office supplies, etc. |
Over 20 |
Prompt payment, advance payment, payment by contract, etc. |
All over China |
90 |
|
|
International |
Production equipment, chemical raw materials, etc. |
Over 5 |
L/C, T/T, etc. |
India and other countries and regions |
10 |
|
|
OTHER INFORMATION |
SC's purchasing business is carried out at home and abroad, mainly in
domestic market. The importing areas are India and other countries and
regions. With years of operation, subject has established stable purchasing
channels. |
|||||
NOTE TO CREDIT RECORD
|
Note |
ELECTRICITY
CONSUMPTION RECORD
No electricity
consumption record of subject can be obtained as the electricity consumer may
not be filed with subject's name.
QUALIFICATIONS & TRENDS
|
- |
Patent Name |
Patent Type |
Status |
Application No. |
Application date |
Classification |
Publication No. |
|
1 |
A recombinant
Escherichia coli and a method for conversion to produce 5- methyl pyrazine
-2- carboxylic acid |
Invention |
Published |
CN201711325652.2 |
2017-12-13 |
C12N1/21(2006.01)I;
C12N15/70(2006.01)I; C12P17/10(2006.01)I; C12R1/19(2006.01)N |
CN107974428A |
|
2 |
A preparation
method of 5 carboxyl methyl pyrazine 2 carboxylic acid |
Invention |
Published |
CN201710903442.0 |
2017-09-29 |
C12P17/12(2006.01)I;
C12R1/06(2006.01)N |
CN107541532A |
|
3 |
A preparation
method of glipizide |
Invention |
Published |
CN201710842829.X |
2017-09-18 |
A61K9/20(2006.01)I;
A61K31/426(2006.01)I; A61K47/40(2006.01)I; A61P19/06(2006.01)I |
CN107468661A |
|
4 |
A preparation
method of glipizide |
Invention |
Published |
CN201710811375.X |
2017-09-11 |
C07D241/24(2006.01)I |
CN107434788A |
|
5 |
A preparation
method of the substance F of Da La non |
Invention |
Published |
CN201710735616.7 |
2017-08-24 |
C07D498/20(2006.01)I |
CN107698606A |
|
6 |
A preparation
method of omeprazole |
Invention |
Published |
CN201710608783.5 |
2017-07-25 |
C07D401/04(2006.01)I |
CN107382963A |
|
7 |
A kind of fat -
lowering health food |
Invention |
Published |
CN201710585584.7 |
2017-07-18 |
A23L33/125(2016.01)I;
A23L33/15(2016.01)I; A23L33/24(2016.01)I |
CN107296281A |
|
8 |
A preparation
method of alimine alpha crystal |
Invention |
Published |
CN201710548726.2 |
2017-07-07 |
C07D401/12(2006.01)I |
CN107188885A |
|
9 |
The preparation
method of the coupling impurity of piperyl hydrochloride |
Invention |
Published |
CN201710516984.2 |
2017-06-29 |
C07D311/28(2006.01)I |
CN107118191A |
|
10 |
A preparation
method of the open loop impurity of the sodium in the sodium lock |
Invention |
Published |
CN201710441698.4 |
2017-06-13 |
C07C51/16(2006.01)I;
C07C51/285(2006.01)I; C07C59/84(2006.01)I |
CN107353195A |
|
11 |
A preparation
method of montelukast sodium impurity D |
Invention |
Published |
CN201710308464.2 |
2017-05-04 |
C07D215/18(2006.01)I |
CN106928138A |
|
12 |
A preparation
method of two benzylamine hydrochloride |
Invention |
Published |
CN201710225957.X |
2017-04-08 |
C07C209/62(2006.01)I;
C07C211/27(2006.01)I; C07C231/12(2006.01)I; C07C233/03(2006.01)I |
CN107089918A |
|
13 |
A
crystallization method for preparation of high stacking density glipizide |
Invention |
Approval Valid |
CN201710168249.7 |
2017-03-21 |
C07D241/24(2006.01)I |
CN106977466A |
|
14 |
A preparation
method of high purity glipizide crystal I |
Invention
authorization |
Published |
CN201710163744.9 |
2017-03-20 |
C07D241/24(2006.01)I |
CN106866552B |
|
15 |
A preparation
method for the crystallization of candesartan ester |
Invention |
Published |
CN201710145305.5 |
2017-03-13 |
C07D403/10(2006.01)I |
CN106977496A |
|
16 |
Preparation of
high purity candesartan crystal I |
Invention |
Published |
CN201710088154.4 |
2017-02-20 |
C07D403/10(2006.01)I;
A61K31/4184(2006.01)I; A61P9/12(2006.01)I |
CN106866633A |
|
17 |
Preparation of
acetamiprid intermediate acetamiprid |
Invention |
Published |
CN201611142216.7 |
2016-12-13 |
C07D205/04(2006.01)I |
CN106588736A |
|
18 |
Method for
preparing donepezil hydrochloride related substance E |
Invention |
Published |
CN201611056290.7 |
2016-11-26 |
C07D211/32(2006.01)I |
CN106631989A |
|
19 |
Determination of
R purity of gliclazide succinate |
Invention |
Published |
CN201611003141.4 |
2016-11-15 |
G01N30/74(2006.01)I;
G01N30/06(2006.01)I; G01N30/86(2006.01)I |
CN106526047A |
|
20 |
A preparation
method of glipizide impurity I |
Invention |
Approval Valid |
CN201610973571.2 |
2016-11-07 |
C07C303/40(2006.01)I;
C07C311/64(2006.01)I |
CN106543042A |
Note: Maximum 20
records are showed for the client’s reference.
EXPORT/IMPORT
PERMIT
|
EXPORT/IMPORT
PERMIT |
Yes |
IMPORT / EXPORT
DETAILS
|
2016 Import /
Export Volume (USD 1,000) |
|
|
Import Volume |
Export Volume |
|
- |
3,789.00 |
|
||||||
|
|
||||||||||||||||
|
||||||
|
|
||||||||||||||||
|
2015 Import /
Export Volume (USD 1,000) |
|
|
Import Volume |
Export Volume |
|
163.00 |
1,902.00 |
|
||||||
|
|
||||||||||||||||
|
||||||||||
|
|
||||||||||||||||
|
Employee Number |
5,000 |
|
OTHER INFORMATION |
SC's staff
confirmed the above information. |
ADMINISTRATIVE INFORMATION
ADMINISTRATIVE
LICENSES & IDENTIFICATIONS
|
- |
License No. |
License Nam e |
|
1 |
Wei An Jian Zhi
Wei Shen Zi [2016]02 |
Review of pre
evaluation report on occupational hazards in construction projects |
|
2 |
Lu 20160179 |
Drug production
license |
|
License No. |
Wei An Jian Zhi
Wei Shen Zi [2016]02 |
|
License Name |
Review of pre
evaluation report on occupational hazards in construction projects |
|
Issuing date |
2016-02-18 |
|
Issuing party |
Bureau of Safety
Production Supervision and Administration - Weihai City |
|
License Content |
Raw material
production project of Wendeng branch |
|
License No. |
Lu 20160179 |
|
License Name |
Drug production
license |
|
Issuing date |
2016-01-01 |
|
Expire date |
2020-12-31 |
|
Issuing party |
Food and Drug
Administration of Shandong Province |
|
License Content |
APIs
(levamlodipine besylate, Trazosin hydrochloride, rofofuster, benzoate A Glenn
Dean, cicenetine phosphate, celecoxib, lansoprazole, etopride hydrochloride,
bupropion hydrochloric acid, oxo Bunin hydrochloride) |
As of the
reporting date, no related record about subject is found through below sources:
A. Website of Tax
Bureau of China;
B. Website of
local Tax Bureau of subject's location;
C. Taxpayer
information of database.
As of the
reporting date, no related record about subject is found through below sources:
A. Website of Tax
Bureau of China;
B. Website of
local Tax Bureau of subject's location;
C. Taxpayer
information of database.
As of the
reporting date, no related record about subject is found through below sources:
A. Major
telecommunication operators of China;
B.
Telecommunication information of database.
FINANCIAL INFORMATION
DETAILED FINANCIAL
INFORMATION (UNIT: CNY 1,000)
Financial Note:
Due to the lack of a clear government policy regarding the transparency of
enterprise financial information, some financial items might be missing in the
financial statements, causing possible inequality between the sum of the
provided items and the provided total numbers.
|
Assets |
|
|
|
Year |
2016-12-31 |
2017-12-31 |
|
Report
Type |
Annual Report |
Annual Report |
|
Statement
Type |
Individual |
Individual |
|
Source |
Tax Bureau |
Tax Bureau |
|
Audited or
Not |
Unknown |
Unknown |
|
Cash and
Equivalents |
7,776 |
2,899 |
|
Notes
Receivable |
1,586 |
14,555 |
|
Accounts
receivable |
10,957 |
10,916 |
|
Advances to
Suppliers |
10,938 |
2,306 |
|
Other Accounts
Receivable |
107,361 |
14,567 |
|
Inventories |
51,081 |
71,612 |
|
Total Current
Assets |
189,699 |
116,855 |
|
Long-term Equity
Investment |
15,000 |
- |
|
Original Value
of Fixed Assets |
58,188 |
164,011 |
|
Accumulated
Depreciation |
24,449 |
41,140 |
|
Net Fixed
Assets |
33,739 |
122,870 |
|
Fixed Assets
Depreciation Reserves |
0 |
0 |
|
Fixed
Assets |
33,739 |
122,870 |
|
Project Being
Constructed |
43,582 |
163,913 |
|
Engineering
Materials |
- |
20 |
|
Liquidation Of
Fixed Assets |
- |
2,097 |
|
Intangible
Asset |
8,084 |
64,182 |
|
Long-term fees
to be deferred |
5,721 |
596 |
|
Other
Non-Current Assets |
- |
22,125 |
|
Total
Non-Current Assets |
106,126 |
375,803 |
|
Total
Assets |
295,825 |
492,658 |
|
Liabilities |
|
|
|
Year |
2016-12-31 |
2017-12-31 |
|
Short Term
Borrowings |
50,000 |
70,000 |
|
Accounts
Payable |
12,612 |
26,226 |
|
Advances from
Customers |
4,353 |
10,634 |
|
Accrued
Payroll |
4,494 |
6,806 |
|
Taxes
Payable |
209 |
5,303 |
|
Other Account
Payable |
87,012 |
69,612 |
|
Total Current
Liabilities |
158,680 |
188,581 |
|
Deferred Income
Tax Liabilities |
698 |
698 |
|
Other
Non-Current Liabilities |
12,688 |
67,000 |
|
Total
Non-Current Liabilities |
13,386 |
67,698 |
|
Total
Liabilities |
172,066 |
256,279 |
|
Share Capital
(Paid-in Capital) |
10,000 |
90,000 |
|
Surplus Reserve |
5,000 |
5,000 |
|
Undistributed
Profits |
108,759 |
141,379 |
|
Total Owner’s
Equity |
123,759 |
236,379 |
|
Total
Liabilities and Owner's Equity |
295,825 |
492,658 |
|
Income
Statement |
|
|
|
Year |
2016-12-31 |
2017-12-31 |
|
Operating Income |
153,096 |
200,014 |
|
Operating Cost |
78,132 |
104,372 |
|
Tax and Associate
Charge |
1,167 |
2,365 |
|
Operating Gross
Profit |
73,797 |
93,277 |
|
Other Business
Income |
566 |
483 |
|
Operating
Expenses |
10,867 |
14,149 |
|
Administrative
Expenses |
42,272 |
57,989 |
|
Financial
Expenses |
2,525 |
4,105 |
|
Operating Profit |
18,699 |
17,517 |
|
Investment
Income |
-2,125 |
50 |
|
Non-operating
Income |
2,392 |
24,262 |
|
Non-operating
Expenses |
42 |
467 |
|
Total Profit |
18,924 |
41,362 |
|
Income Tax |
1,704 |
13,342 |
|
Net Profit |
17,220 |
28,020 |
GROWTH RATE OF
MAJOR FINANCIAL
|
|
2016 |
Growth(%) |
2017 |
|
Operating Income |
153,096 |
30.65 |
200,014 |
|
Total Assets |
295,825 |
66.54 |
492,658 |
|
Working Capital |
31,019 |
-331.23 |
-71,726 |
|
Total Profit |
18,924 |
118.57 |
41,362 |
|
Net Profit |
17,220 |
62.72 |
28,020 |
|
Total
Liabilities |
172,066 |
48.94 |
256,279 |
|
Total Owner’s
Equity |
123,759 |
91.00 |
236,379 |
|
Total Current
Assets |
189,699 |
-38.40 |
116,855 |
|
Total Current
Liabilities |
158,680 |
18.84 |
188,581 |
|
Fixed Assets |
33,739 |
264.18 |
122,870 |
IMPORTANT RATIO
|
Profitability |
2016 |
2017 |
|
Return on net
assets (%) |
13.91 |
11.85 |
|
Return on total
assets (%) |
5.82 |
5.69 |
|
Net profit
margin (%) |
11.25 |
14.01 |
|
Gross Profit
Margin (%) |
48.20 |
46.64 |
|
Operation
capacity |
2016 |
2017 |
|
Turnover of
total assets |
0.52 |
0.41 |
|
Turnover of
current assets |
0.81 |
1.71 |
|
Turnover of
account receivable |
13.97 |
18.32 |
|
Turnover Days of
Accounts Receivable |
25.77 |
19.65 |
|
Solvency |
2016 |
2017 |
|
Liabilities to
assets ratio (%) |
58.16 |
52.02 |
|
Current ratio |
1.20 |
0.62 |
|
Quick ratio |
0.87 |
0.24 |
|
Development
capacity |
2016 |
2017 |
|
Yearly Growth of
Operating Income (%) |
- |
30.65 |
|
Yearly growth of
gross profit (%) |
- |
26.40 |
|
Yearly growth of
total assets (%) |
- |
66.54 |
FINANCIALS &
ANALYSIS
|
Financial Note |
SC's paid-up
capital of 2016 is inconsistent with that of 2017 due to the registered
capital change. |
INDUSTRY INFORMATION
|
SIC (China) |
2710,Production of Original Medicine of Chemical Drugs 【Major】 |
|
ISIC |
2100,Manufacture of medicines, medical products and herbal medicines |
|
NACE |
21.1,Manufacture of medicines, medical products and herbal medicines |
INDUSTRY FINANCIAL AVERAGE
|
- |
2016 |
Subject |
Best(10%) |
Average |
Worst(10%) |
|
Solvency |
Liabilities to Assets Ratio (%) |
58.16 |
47.70 |
55.62 |
74.20 |
|
Current ratio |
1.20 |
2.35 |
1.59 |
0.98 |
|
|
Quick ratio |
0.87 |
1.47 |
0.99 |
0.61 |
|
|
Development Capacity |
Yearly Growth of Operating Income (%) |
- |
34.90 |
15.46 |
-6.90 |
|
Yearly Growth of Gross Profit (%) |
- |
28.37 |
6.81 |
-9.60 |
|
|
Yearly Growth of Total Assets (%) |
- |
29.92 |
11.88 |
-4.02 |
|
|
Profitability |
Return on net assets (%) |
13.91 |
25.76 |
12.23 |
-2.10 |
|
Return on total assets (%) |
5.82 |
15.31 |
8.88 |
-1.57 |
|
|
Gross profit margin (%) |
48.20 |
53.54 |
36.45 |
14.23 |
|
|
Operation Capacity |
Turnover of total assets |
0.52 |
1.66 |
0.69 |
0.22 |
|
Turnover of current assets |
0.81 |
3.09 |
1.85 |
0.98 |
|
|
Turnover days of account receivable |
25.77 |
25.44 |
56.57 |
95.24 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 67.32 |
|
|
1 |
INR 91.25 |
|
Euro |
1 |
INR 80.51 |
|
CNY |
1 |
INR 10.64 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
VAR |
|
|
|
|
Report Prepared
by : |
SYL |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.